RevCycle Intelligence September 14, 2020
Jacqueline LaPointe

Thousands of hospitals are urging HHS to stop drug companies from restricting discounts under the 340B drug pricing program; AHA finds 340B hospitals provided $64B in community benefits.

The controversy surrounding the notorious 340B Drug Pricing Program continues with more than 1,100 hospitals now urging HHS to stop pharmaceutical companies from refusing discounts for drugs covered by the federal program.

The Sept. 10th letter to HHS Secretary Alex Azar was written by hospitals in response to a growing number of major pharmaceutical companies reining in the discounts they must offer to entities in the program.

For example, AstraZeneca and Eli Lilly recently announced that they would no longer provide lower drug prices for 340B entities for any of its drugs...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Govt Agencies, Health System / Hospital, Healthcare System, HHS, Pharma, Pharma / Biotech, Pricing / Spending, Provider
Related Articles:
Hospitals, physicians clash over FTC rule banning non-compete agreements
STAT+: Why a British hospital, and not a drugmaker, is trying to get a rare disease therapy approved
34,000 medication errors reported last year despite investments in tech
AI degrades our work, nurses say
What Sets Board and Care Facility Apart From Other Senior Care Options?

Share This Article